InvestorsHub Logo
Followers 3
Posts 288
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Tuesday, 03/14/2023 6:11:02 PM

Tuesday, March 14, 2023 6:11:02 PM

Post# of 3283
New poziotinib data will be presented at AACR 2023 meeting by Heymach group. Abstract title: "Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors''. They demonstrated that poziotinib may retain anti-tumor cell activity in HER2 mutant tumor cells with acquired resistance to HER2 ADCs such as Enhertu.
https://www.abstractsonline.com/pp8/#!/10828/presentation/9193